

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

---

1. (Previously Amended) A liposomal topotecan unit dosage form, said unit dosage form comprising:

a lipid; and

a topotecan dosage of from about 0.01 mg/M<sup>2</sup>/dose to about 7.5 mg/M<sup>2</sup>/dose, wherein said liposomal topotecan unit dosage form has a drug:lipid ratio by weight of about 0.05 to about 0.2 and wherein said lipid comprises a mixture of sphingomyelin and cholesterol.

2. (Previously Amended) The liposomal topotecan unit dosage form of claim 1, wherein said drug:lipid ratio by weight is about 0.05 to about 0.15.

3. (Canceled)

4. (Currently Amended) The liposomal topotecan unit dosage form of claim 1, wherein said lipid comprises sphingomyelin and cholesterol in a molar ratio ~~by weight~~ of about ~~30:70~~70:30 to about ~~60:40~~40:45.

5. (Original) The liposomal topotecan unit dosage form of claim 1, comprising from about 1 mg/M<sup>2</sup>/dose to about 4 mg/M<sup>2</sup>/dose of topotecan.

6. (Original) A liposomal topotecan formulation, wherein said liposomal topotecan formulation retains greater than 50% active lactone species after 12 hours in blood circulation.

7. (Original) The liposomal topotecan formulation of claim 6, wherein said liposomal topotecan formulation retains greater than 80% active lactone species after 12 hours in blood circulation.

8. (Original) A liposomal topotecan formulation comprising topotecan, sphingomyelin, cholesterol and a divalent cation ionophore.

9. (Canceled)

10. (Previously Amended) The liposomal topotecan formulation of claim 8, comprising a drug:lipid ratio by weight of about 0.05 to about 0.2.

11. (Previously Amended) The liposomal topotecan formulation of claim 10, wherein said drug:lipid ratio by weight is about 0.05 to about 0.15.

12. (Canceled)

13. (Original) A method of treating a solid tumor in a human afflicted therewith, said method comprising administering to said human an effective amount of a topotecan dosage of claim 1 in a pharmaceutically acceptable carrier.

14. (Currently Amended) The method of claim 13, wherein said solid tumor is selected from the group consisting of solid tumors of the lung, mammary, and colon-~~and~~ prostate.

15. (Currently Amended) The method of claim 13, further comprising ~~co~~ administration of a treatment for neutropenia or platelet deficiency.

16. (Canceled)

(17) (Currently Amended) A method of treating solid tumors in a mammal, said method comprising: *333 mg/kg/dose - 2.5 mg/kg/dose*

administering to said mammal having a solid tumor of the lung, mammary and/or colon a liposomal topotecan formulation comprising from about 0.01 mg/M<sup>2</sup>/dose to about 7.5 mg/M<sup>2</sup>/dose of topotecan for an interval regime, ~~wherein said interval regime is once a day for at least two consecutive days.~~

18. (Original) The method of treating solid tumors of claim 17, wherein said interval regime is at least once a week.

19. (Original) The method of treating solid tumors of claim 17, wherein said interval regime is at least once every two weeks.

20. (Original) The method of treating solid tumors of claim 17, wherein said interval regime is at least once every three weeks.

B<sup>2</sup>  
21. (Previously Presented) The method of treating solid tumors of claim 17, wherein said liposomal topotecan formulation has a drug:lipid ratio by weight of about 0.05 to about 0.2.

22. (Canceled)

(23) (Currently Amended) A liposomal camptothecin unit dosage form, said unit dosage form comprising a lipid, a camptothecin dosage of from about 0.015 mg/M<sup>2</sup>/dose to about 1 mg/M<sup>2</sup>/dose and having a drug:lipid ratio by weight of about 0.05 to about 0.2 and wherein said lipid comprises a mixture of sphingomyelin and cholesterol.

24. - 25. (Canceled)

B<sup>2</sup> 26. (New) The method of treating solid tumors of claim 17, wherein said interval regime is once a day for at least two consecutive days.

---